Bristol-Myers Squibb (NYSE:BMY) Stock Price Down 0.3%

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) fell 0.3% during trading on Wednesday . The stock traded as low as $43.74 and last traded at $43.89. 1,990,979 shares were traded during trading, a decline of 87% from the average session volume of 15,625,271 shares. The stock had previously closed at $44.04.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on BMY shares. BMO Capital Markets lowered their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating on the stock in a research note on Friday, April 26th. Societe Generale downgraded shares of Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a report on Monday, March 11th. Barclays reduced their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an "equal weight" rating on the stock in a research note on Friday, April 26th. Redburn Atlantic lowered Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, StockNews.com lowered Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Monday, April 15th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $60.00.

Bristol-Myers Squibb Stock Down 0.8 %

The company's 50-day simple moving average is $50.11 and its two-hundred day simple moving average is $50.48. The firm has a market cap of $88.52 billion, a PE ratio of -14.09, a PEG ratio of 14.82 and a beta of 0.45. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analysts' expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb's quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the firm earned $2.05 earnings per share. On average, analysts predict that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 5.50%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb's payout ratio is -77.42%.

Institutional Investors Weigh In On Bristol-Myers Squibb

A number of large investors have recently modified their holdings of BMY. McClarren Financial Advisors Inc. grew its holdings in shares of Bristol-Myers Squibb by 532.7% during the 4th quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company's stock worth $96,000 after acquiring an additional 1,582 shares during the period. Institute for Wealth Management LLC. lifted its holdings in shares of Bristol-Myers Squibb by 1.0% during the 4th quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company's stock valued at $1,542,000 after buying an additional 296 shares during the period. Herold Advisors Inc. lifted its stake in shares of Bristol-Myers Squibb by 3.2% in the 3rd quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company's stock worth $1,954,000 after purchasing an additional 1,051 shares during the period. Kestra Private Wealth Services LLC grew its position in shares of Bristol-Myers Squibb by 9.5% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company's stock valued at $8,115,000 after acquiring an additional 12,121 shares during the period. Finally, Metis Global Partners LLC grew its holdings in Bristol-Myers Squibb by 14.8% during the third quarter. Metis Global Partners LLC now owns 101,772 shares of the biopharmaceutical company's stock valued at $5,907,000 after purchasing an additional 13,122 shares during the period. Institutional investors own 76.41% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.